August 26, 2014Journal of Clinical OncologyOpen Access

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

View Full Paper

Ask AI

Bookmark

Authors

JKJames N. KochenderferNational Institutes of Health MDMark E. DudleyUniversity of the Sciences SKSadik H. KassimOffice of the Chief Scientist

Discussion

Member takes

Implication

Clinical assessment demonstrates effective treatment of refractory B-cell malignancies with anti-CD19 CAR T cells, highlighting a viable targeted immunotherapy approach.

Key Points

Genetically modified autologous T cells targeting CD19 effectively treat chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies.
Assessment evaluating autologous anti-CD19 CAR T cells examines therapeutic response profiles and safety parameters in patients with advanced CD19-positive tumors.
Findings support chimeric antigen receptor T-cell administration as an effective strategy for heavily pretreated, chemotherapy-resistant B-cell malignancies.

Cite This Study

Kochenderfer et al. (2014) studied this question.

synapsesocial.com/papers/68f8a73924b0bc2d8590067f https://doi.org/10.1200/jco.2014.56.2025

View Full Paper

Ask AI

Bookmark

Implication

Clinical assessment demonstrates effective treatment of refractory B-cell malignancies with anti-CD19 CAR T cells, highlighting a viable targeted immunotherapy approach.

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

Discussion

Member takes

Implication

Key Points

Cite This Study

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider